The Food and Drug Administration on Sept. 25 approved a new therapy for advanced breast cancer, based on data from a phase 3 clinical trial.
Regulators said in a statement that they approved imlunestrant, also known as Inluriyo, from Eli Lilly.
The therapy, an estrogen receptor antagonist, is cleared for adults who have advanced or metastatic breast cancer with estrogen receptor-1 mutations.
Metastatic breast cancer, also called Stage IV breast cancer, occurs when the disease has spread beyond the breast and nearby lymph nodes to other parts of the body, most commonly the bones, lungs, liver, or brain.
Some breast cancers develop estrogen receptor-1 mutations, which make estrogen receptors overly active. These receptors normally help regulate cell growth, but when mutated, they can drive cancer progression….